Blog

SAN MATEO, CA / ACCESS Newswire / June 2, 2025 / Sierra Ventures, a leading early-stage venture capital firm focused on enterprise and deep tech innovation, is excited to announce that Ashish Kakran has joined the firm as a Partner. Ashish will source investments across enterprise infrastructure, focusing on artificial intelligence, cloud infrastructure, and cybersecurity.

Ashish brings deep domain expertise and a strong investment track record to Sierra Ventures. Before joining the firm, he invested in category-defining companies, including Cohere (a leader in generative AI), Harness (DevOps automation), Isovalent (acquired by Cisco), Opaque (confidential computing for AI), and Exaforce (SOC automation). He is known for partnering closely with technical founders and helping them scale go-to-market efforts and product strategy from inception to growth.

In addition to his investing track record, Ashish is a well-regarded voice on technology trends, with bylines in TechCrunch and VentureBeat, and recognition from VC Journal’s “40 Under 40” and Business Insider’s “Rising Stars in VC.”

“Ashish combines deep technical fluency with a clear vision for where enterprise infrastructure is heading,” said Mark Fernandes, Managing Partner at Sierra Ventures. “He sees around corners in fast-moving categories like AI and security, and founders value his ability to connect product ambition with market reality early in the build.”

Ashish actively mentors entrepreneurs through programs at UC Berkeley, IIT, and Carnegie Mellon, and leads several investor communities, including the Bay Area chapter of Kellogg VCs. He holds a BS in Computer Science from IIT and an MBA from the Kellogg School of Management.

“Sierra Ventures has a strong track record of backing and supporting technical founders from the earliest stages of their journey,” said Kakran. “The AI stack is being rewritten in real-time, from infrastructure to security to applied intelligence and I’m eager to partner with technical founders who are reimagining how the enterprise is built and powered in this new era.”

Ashish’s addition strengthens Sierra Ventures’ commitment to investing in the next generation of enterprise software and intelligent infrastructure platforms.

About Sierra Ventures
Sierra Ventures is an early-stage venture firm focused on the future of Enterprise and Frontier Technologies. With four decades of experience and over $2 billion in assets under management, Sierra has created a vast network of successful entrepreneurs, Global 1000 CXOs, operational executives, and deep domain experts, providing a platform for entrepreneurs worldwide. Learn more at www.sierraventures.com.

MEDIA CONTACTS:

Anne Gherini, CMO at Sierra Ventures
E: anne@sierraventures.com
Telephone: (650) 233-6116

Nina Pfister, Co-Founder of MAG PR
E: nina@mooringadvisorygroup.com

SOURCE: Sierra Ventures

View the original press release on ACCESS Newswire

MCLEAN, VA / ACCESS Newswire / June 2, 2025 / Gladstone Alternative Income Fund (“Gladstone Alternative” or the “Fund”) announced today that its board of trustees declared monthly cash distributions to shareholders for the month of June, increasing the daily dividend rate by 1.149%, in comparison to the May dividend rate. The June distribution amount is $0.00176 per calendar day for each issued and outstanding Class A share, Class C share, and Class I share for the period beginning June 1, 2025 and ending June 30, 2025 (for shareholders who own shares all 30 days in June, the distribution will total $0.0528 per share). The distributions will be paid on July 1, 2025 for Dividend Reinvestment Plan (“DRIP”) participants and for non-DRIP participants.

John Sateri, President of Gladstone Alternative, noted, “We are pleased to announce the fourth consecutive monthly dividend for Gladstone Alternative, continuing our commitment to delivering consistent income to our investors. We look forward to continuing to create long-term value in the months and years ahead by generating sustainable returns for our shareholders while providing them access to a diversified portfolio of private credit and equity investments.”

About Gladstone Alternative Income Fund

Gladstone Alternative Income Fund is a non-diversified, unlisted, closed-end management investment company registered under the Investment Company Act of 1940 and is operating as an interval fund. The Fund seeks to achieve and grow current income by investing primarily in directly originated loans to lower and middle market private businesses in the United States, broadly syndicated loans and commercial real estate loans.

Investors are advised to carefully consider the investment objectives, risks and charges, and expenses of Gladstone Alternative Income Fund before investing. The prospectus, dated November 7, 2024, which has been filed with the U.S. Securities and Exchange Commission, and as supplemented from time to time, contains this and other information about the Fund and should be read carefully before investing. You may get these documents for free by visiting the Fund’s website at www.gladstoneintervalfund.com or by visiting EDGAR on the SEC’s website at www.sec.gov. To obtain a copy of the prospectus, you may also contact Gladstone Securities, LLC, the dealer manager and distributor for this offering, which will arrange to send you the prospectus if you request it by calling toll-free at (833) 849-5993.

For further information, please visit our website at www.gladstoneintervalfund.com.

SOURCE: Gladstone Alternative Income Fund

View the original press release on ACCESS Newswire

BOCA RATON, FL / ACCESS Newswire / June 2, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) announced today that, Christopher Ruddy, Newsmax CEO, has been invited to present at the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow,” presented by Maxim Group LLC, on Wednesday, June 4, 2025 at 12:00 p.m. ET – 12:30 p.m. ET.

Newsmax will be taking part in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow.” The rapid evolution of technology is paving the way for disruption across all industries, including healthcare, drones, consumer IoT, business solutions, gaming & entertainment, and more. Maxim Senior Analysts will facilitate engaging dialogues with CEOs and key management of diverse companies who have their attention on technology and how it will impact and grow their business.

This conference will be live on M-Vest. To attend, sign up to become an M-Vest member.

Click here to learn more and reserve your seat

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major cable and satellite systems. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Media, Inc.

About Maxim Group LLC

Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit maximgrp.com.

Investor Contacts

Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

DALLAS, TX / ACCESS Newswire / June 2, 2025 / Career Management Partners (CMP), a minority and woman owned talent and transition firm, believes no professional should feel trapped by a career rut or defined by a layoff. To shatter that stigma and reignite confidence, CMP proudly launches the inaugural International Career Pivot Day on June 21, 2025.

View the original press release on ACCESS Newswire

VANCOUVER, BC / ACCESS Newswire / June 2, 2025 / 1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE:TGIF)(OTC PINK:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce the completion of the amended Membership Interest Purchase Agreement (the “MIPA”) entered into by its wholly owned subsidiary, FN Pharmaceuticals, and Mr. Caleb Zobrist (the “Seller”) to acquire his nine percent (9%) of the issued and outstanding membership interests of Alternative Medicine Association LC (“AMA”) (refer to news releases dated April 8, 2024 and May 22, 2025). The transaction closed on May 30, 2025.

With the completion of the MIPA, FN Pharmaceuticals now owns 100% of the membership interest in AMA, the Company’s cultivation and production subsidiary.

Under the amended MIPA, the purchase price (the “Purchase Price”) for the Membership is a total of USD$50,00, payable to the Seller USD$25,000 in cash and USD$25,000 through the issuance of shares of common stock of 1933 Industries (the “Shares”). The final number of Shares to be issued to the Seller is 5,503,450 as determined via the 10 day VWAP price of the Shares on November 27, 2024, being the date the transactions contemplated by the MIPA were approved by the Nevada Cannabis Compliance Board.

The Shares are subject to a hold period in Canada expiring on October 1, 2025. Additional restrictions will apply pursuant to the Securities Act of 1933, as amended.

As Mr. Zobrist was a senior officer of the Company at the time the MIPA was entered into, he is a “related party” to the Company within the meaning of Multilateral Instrument 61-101- Protection of Minority Security Holders in Special Transactions (“MI 61-101”). As such, the transaction constitutes a “related party transaction” within the meaning of MI 61-101.

The Company intends to rely on exemptions from formal valuation and the minority shareholder approval requirements of MI 61-101 found in sections 5.5(a) and 5.7(1)(a) of MI 61-101 as the fair market value of the transaction does not constitute more than the 25% of the Company’s market capitalization.

About 1933 Industries Inc.

1933 Industries is a Nevada-based licensed wholesale producer, focused on the cultivation and extraction of a large portfolio of cannabis consumer products in a variety of formats under its flagship brands, Alternative Medicine Association (AMA) and Level X. Its product offerings are cultivated at the Company’s 68,000 sq. ft. indoor facility and marketed directly to retail dispensaries. AMA branded flower, infused pre-rolls, and in-house boutique concentrates consistently rank as the top products sold in Nevada. For more information, please visit www.1933industries.com

For further information please contact:
Alexia Helgason, VP, Investor Relations
604-728-4407
alexia@1933industries.com

Brian Farrell, Chairman and CEO
brian@1933industries.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: 1933 Industries Inc.

View the original press release on ACCESS Newswire

A Universal Search Experience That Brings Speed, Simplicity, and Context to Business Intelligence

SAN FRANCISCO, CA / ACCESS Newswire / June 2, 2025 / GoodData, the AI-native analytics platform, today introduced AI Smart Search, an intelligent search experience designed to help users instantly locate analytics content across their workspace. Whether it’s a dashboard, visualization, or saved insight, Smart Search eliminates the guesswork of navigation and puts the right information at your fingertips, within seconds.

By combining modern UX patterns with AI-powered semantic understanding, this new feature brings the ease of consumer-grade search tools to enterprise analytics. From quick lookups to deep discovery, Smart Search is built to support everyone, from data-savvy professionals to analytics engineers, making it easier than ever to find, reuse, and explore what already exists in your analytics environment.

Search Anything. Instantly. Intelligently.

With a single keystroke, users can access a global search bar embedded in the main workspace navigation. This AI-native feature goes beyond keyword matching – it uses vector-based semantic similarity to surface the most relevant results based on names, descriptions, and tags.

Key Capabilities Include:

• Semantic Matching: Understands the meaning behind your query to deliver relevant dashboards, visualizations, and metrics, even when the phrasing isn’t exact (e.g., searching for “monthly revenue trends” can return insights titled “Revenue over time” or “Monthly sales growth”).

• Contextual Previews: Each result includes metadata like object type, last edited timestamp, and confidence score.

• Real-Time Feedback: Results appear after typing each character, updating dynamically without needing to press Enter.

• Historical Recall: Shows recent searches by default, helping users return to past explorations quickly.

• Accessible Navigation: Fully keyboard-operable, navigate with arrows, select with Enter, exit with Esc, and more, for an inclusive and efficient experience.

• Permission-Aware Results: Users see only what their access level allows, ensuring privacy and compliance across roles.

AI-Powered Architecture

Under the hood, GoodData AI Smart Search is built on a scalable and secure foundation that ensures speed and precision at scale:

• Distributed Qdrant Vector Store: Provides high availability and auto-scalability for fast and reliable search performance across enterprise environments.

• Multi-Lingual Small Language Model: Generates embeddings for semantic layer entities in near-real-time, enabling support for diverse language inputs.

• Advanced Re-Ranking Algorithms: Multiple language models are used to re-rank search results, optimizing for the most contextually relevant answers.

• Fully Embedded, Perimeter-Secure Deployment: All processing is handled within the GoodData platform boundary, so no data ever leaves your secure environment. This applies to any deployment type – on-prem or in GoodData Cloud.

“GoodData AI Smart Search brings the intelligence of AI and the familiarity of modern search UX into enterprise analytics,” said Jan Franek, Senior Product Manager at GoodData. “It’s not just about finding dashboards-it’s about accelerating insight discovery while reducing duplication and friction.”

For All Users-from Prosumers to Power Builders

• Business Users: Skip creating new reports-find existing answers fast.

• Analytics Engineers: Locate elements to edit, reuse, or integrate in seconds.

• Developers: Embed Smart Search into custom applications for a tailored, white-labeled user experience.

Composable Search for Every Workflow

GoodData AI Smart Search is designed for flexibility, whether used as a native feature within the GoodData platform or integrated into your own applications. Thanks to GoodData’s composable architecture, businesses can embed the search experience via APIs and SDKs, delivering fast, contextual insight discovery directly within their workflows. It’s a powerful extension of the AI ecosystem, ensuring consistency, security, and scalability from the ground up.

Looking Ahead

GoodData AI marks the beginning of a new era of BI, where AI isn’t just a bolt-on assistant but a core, intelligent layer within the analytics stack. As the platform evolves, expect deeper orchestration and integration, and more intuitive user experiences, delivered at scale, securely, and in full alignment with enterprise needs.

AI Smart Search is one of the first major milestones in this journey along with GoodData AI Assistant – an interactive, conversational interface that helps users generate insights, build dashboards, and interpret data using natural language. Together, these capabilities represent a fundamental shift toward a more intelligent, context-aware analytics experience.

AI will continue expanding across every layer of the GoodData platform, powering intelligence everywhere it’s needed.

---

About GoodData

GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.

Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.

For more information, visit GoodData’s website and follow GoodData onLinkedIn, YouTube, and Medium.

GoodData Contact

press@gooddata.com

©2025, GoodData Corporation. All rights reserved. GoodData and the GoodData logo are registered trademarks of GoodData Corporation in the United States and other jurisdictions. Other names used herein may be trademarks of their respective owners.

SOURCE: GoodData

View the original press release on ACCESS Newswire

Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026

MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), an emerging leader in age-reversal science, today announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering™ meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions.

Telomir is actively preparing to submit an Investigational New Drug (IND) application by the end of this year for its lead candidate, Telomir-1-a novel small molecule designed to elongate telomeres, regenerate cells, and reverse core mechanisms of biological aging. The Company is gearing up for its pre-IND meeting with the FDA, with the goal of initiating first-in-human dosing in the first half of 2026.

As part of its expanding pipeline, Telomir is advancing a rare-disease exploratory and developmental strategy focused on high-need orphan indications where cellular aging plays a central role. These include:

• Werner’s syndrome, a rare adolescent- or adult-onset disorder often referred to as “adult Progeria,” which is expressed by many features of premature aging, including early graying, cataracts, metabolic dysfunction, and cancer predisposition.

• Wilson’s disease, a rare genetic disorder caused by copper accumulation in tissues. Telomir-1 has already demonstrated in preclinical testing copper-modulating capabilities, reversal of copper-induced toxicities and reactive oxygen species production, offering a potential disease-modifying approach that directly addresses the root cause of toxicity and inflammation associated with Wilson’s.

• Progeria, an ultra-rare pediatric condition that causes rapid aging in children, where Telomir-1 has shown in animal models restoration of lifespan and normalization of disease markers.

• Dysphonia, including rare neuromuscular subtypes that impair vocal cord function and may be linked to inflammation and accelerated tissue degeneration.

The Company plans to meet with the FDA to establish novel clinical endpoints across its rare disease programs, aiming to unlock accelerated development pathways and regulatory flexibility.

In parallel, Telomir-1 is also being investigated in autism spectrum disorder, where its potential impact on telomere biology, oxidative stress, neurodegeneration and inflammation may offer a novel therapeutic approach for neurodevelopmental conditions.

Beyond rare and neurological disorders, Telomir has achieved significant preclinical success across a range of high-impact therapeutic areas, underscoring the versatility of its platform:

• Vision Restoration: Structural and functional recovery of the retina in FDA-recognized endpoints in animal models of age-related macular degeneration (AMD).

• Longevity and Aging: Consistent age-reversal, increased lifespan, and improved health in standard aging, Werner’s syndrome and in Progeria models.

• Metabolic Disease: In preclinical models of Type 2 diabetes,Telomir-1 led to the reversal of elevated blood glucose, restoration of insulin sensitivity, improved pancreatic islet function, and a marked reduction in oxidative stress and systemic inflammation.

• Oncology: In a preclinical model of aggressive human prostate cancer, Telomir-1 alone at both low and high doses reduced tumor growth by approximately 50%, while also exhibiting a protective effect on healthy cells. These findings directly counter concerns that telomere-elongating drugs may promote cancer; instead, Telomir-1 actively suppressed tumor progression.

• Infectious Disease: Development of Telomir-Ag2, a novel drug candidate with potent activity against multidrug-resistant bacteria, including MRSA.

“The breadth of our preclinical data showcases the potential of Telomir-1 not just as a treatment-but as a platform for addressing aging-related and rare diseases at the source,” said Erez Aminov, Chief Executive Officer of Telomir. “As we prepare for IND submission and for a pre-IND meeting with the FDA, we look forward to connecting with potential partners at BIO to explore licensing and M&A opportunities that can help accelerate our path to the clinic.”

Dr. Angel, Chief Scientific Advisor at Telomir, added:
“In all my years in drug development, I’ve never seen a molecule with this kind of cross-indication potential. The science behind Telomir-1 is remarkable-it’s addressing cellular aging at its root, and the preclinical data speak for themselves. What excites me most is how this one molecule may have the power to transform how we treat aging-related, metabolic, and rare genetic diseases across the board.”

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

IRS Debt Doesn’t Just Lead to Penalties – It Can Derail Major Life Goals, Warns Clear Start Tax

IRVINE, CA / ACCESS Newswire / June 2, 2025 / For many Americans, back taxes may seem like a personal issue, but the consequences extend far beyond IRS notices. According to Clear Start Tax, a nationally recognized tax resolution firm, unpaid tax debt can severely damage your credit, block financial opportunities, and create lasting setbacks that impact everything from buying a home to securing a loan or job.

“People think of the IRS as separate from their financial reputation,” said the Head of Client Solutions at Clear Start Tax. “But a tax lien or collection activity can hit your credit and your long-term goals harder than you expect.”

What Ignoring Back Taxes Could Really Cost You

Failing to address back taxes doesn’t just leave you with a growing balance – it opens the door to enforcement actions that can affect your income, assets, and long-term financial health. As Clear Start Tax explains, IRS collection efforts often begin quietly but can escalate quickly and aggressively if left unresolved. Some of the most serious consequences include:

• Tax liens can be filed against your property and reported to credit bureaus, reducing credit scores and limiting your ability to borrow.

• Bank levies can drain your accounts with little warning, leaving you without access to needed funds.

• Wage garnishments can reduce your take-home pay and create a cycle of financial instability.

• Interest and penalties compound daily, quickly increasing what you owe.

Clear Start Tax notes that these consequences don’t just harm your current finances – they also delay or destroy future plans, including mortgage approvals, car loans, small business funding, and even job applications with financial background checks.

Credit Damage Can Linger Long After the Tax Is Paid

Even after a tax debt is resolved, the financial damage can linger. Public records like tax liens (when reported) and collection actions can remain on credit reports for years. And if a taxpayer entered into a payment plan late-or only after enforcement began-that history may still reflect negatively in the eyes of lenders or employers.

“Back taxes aren’t just a balance to pay-they can become a barrier to progress,” added the Head of Client Solutions at Clear Start Tax. “We’ve worked with clients who couldn’t refinance their homes or qualify for financing because of unresolved tax issues that were years old.”

How Clear Start Tax Helps Clients Protect Their Credit and Rebuild Confidence

Clear Start Tax offers personalized solutions that do more than just address the debt-they help safeguard credit and prevent long-term damage. The firm works with each client to:

• Conduct a full IRS and credit risk review

• Recommend the right IRS program (such as Offer in Compromise, Installment Agreement, or CNC status)

• Prevent or remove liens and stop garnishments

• Ensure timely filings to maintain eligibility for relief

• Provide guidance on staying compliant to rebuild financial health

With the right strategy and early action, most taxpayers can avoid the worst outcomes and take back control of their financial future.

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire